BCL2 and B-cell chronic lymphocytic leukemia: In addition to BTK inhibitors, such as ibrutinib, two other kinds of targeted drugs have been approved by the US Food and Drug Administration for the treatment of CLL: a BCL-2 inhibitor (venetoclax) and PI3K inhibitors (idelalisib and duvelisib).